Anup Vora, Daniel Marchalik, Hanaa Nissim,
Keith Kowalczyk, Gaurav Bandi, Kevin McGeagh,
John Lynch, Krishnan Venkatesan, Reza Ghasemian,
Jonathan Hwang, Mohan Verghese
Canadian Journal of Urology, Vol.21, No.2, pp. 7222-7227, 2014
Abstract Introduction: Radical cystectomy is associated with significant morbidity and cost, with rates of gastrointestinal complications as high as 30%. Alvimopan is a mu opioid receptor antagonist that has been shown in randomized-control trials to accelerate gastrointestinal recovery in patients undergoing bowel resection with primary anastamosis. We report our experience with gastrointestinal recovery for patients undergoing cystectomy with urinary diversion treated with alvimopan and cost benefit associated.
Materials and methods: Between January 2008 and October 2012, 80 patients underwent radical cystectomy with urinary diversion at two institutions. Forty-two patients in our study did not receive alvimopan preoperatively.… More >